Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors in Laos

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions
Cigarette Smoking
Interventions
DRUG

Nicotine patch

Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.

BEHAVIORAL

Self-help materials (to support smoking cessation)

"Our team has translated and validated the World Health Organization's A guide for tobacco users to quit into Lao language for use as the self-help material in this study."

BEHAVIORAL

Smartphone-based automated treatment for smoking cessation

The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 12-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.

Trial Locations (2)

Unknown

Lao National Cancer Center, Vientiane

Setthathirath Hospital, Vientiane

All Listed Sponsors
collaborator

Setthathirath Hospital

OTHER

collaborator

Lao National Cancer Center

OTHER

collaborator

National Center for Laboratory and Epidemiology, Lao PDR

OTHER

collaborator

National Tobacco Control Committee, Lao PDR

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Oklahoma

OTHER